nattanit suriyaphan @TaDoay
Joined February 2026-
Tweets7
-
Followers1
-
Following6
-
Likes0
🆙#WCLC26 #LCSM Plenary Session 🔥REZILIENT3: Zipalertinib Plus Chemotherapy for 1st Line NSCLC With EGFR Exon 20 Insertions: Results From the Phase 3 Trial 🎙️ @danieltanmd 🎯 PFS HR 0.50 (95%CI 0.34-0.73) 🔢PL03.04 ☑️NCT05973773 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC @EGFRResisters @Exon20Group
🆙#WCLC26 #LCSM Plenary Session 🔥REZILIENT3: Zipalertinib Plus Chemotherapy for 1st Line NSCLC With EGFR Exon 20 Insertions: Results From the Phase 3 Trial 🎙️ @danieltanmd 🔢PL03.04 ☑️NCT05973773 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC @EGFRResisters @Exon20Group
🆙#WCLC26 #LCSM Oral Session 🔥A Phase III Randomized Multicenter Trial of Adjuvant Gefitinib Plus Chemotherapy Versus Chemotherapy in EGFR-Mutant NSCLC 🎙️Dr. Beung-Chul Ahn 🎯Intercalating gefitinib with platinum doublet improved DFS 🎯median DFS 58.8m vs 41.2m 🔢OA04.01 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC @EGFRResisters
🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC 🎙️ @MartinReck2 🔢OA04.02 🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort ☑️NCT05925530 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC
🆙#WCLC26 #LCSM Oral Session 🔥MDT-BRIDGE: Neoadjuvant Durvalumab + Chemotherapy for Resectable/Borderline Resectable Stage IIB-IIIB NSCLC 🎙️ @MartinReck2 🔢OA04.02 🎯Resection Rate 74.6%; pCR 27.3% and 12-Mo EFS 90.1% in Resectable Cohort ☑️NCT05925530 🔗
🆙#WCLC26 #LCSM Oral Session 🔥Phase 2 Study of peri-ope/CRT JS207 (PD-1/VEGF Bispecific Antibody) + Chemo in Unresectable Stage III NSCLC 🎙️ @ThomasW35874311 🔢OA09.03 🎯Surgical Conversion Rate 52.4% (22/42) 🎯pCR 54.5% and MPR 72.7% Among Resected Patients 🎯Grade≥3 TRAEs in 45.2% ☑️NCT06944470 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC
🆙#WCLC26 #LCSM Oral Session 🔥Phase 2 Study of peri-ope/CRT JS207 (PD-1/VEGF Bispecific Antibody) + Chemo in Unresectable Stage III NSCLC 🎙️ @ThomasW35874311 🔢OA09.03 🎯Surgical Conversion Rate 52.4% (22/42) 🎯pCR 54.5% and MPR 72.7% Among Resected Patients 🎯Grade≥3 TRAEs in
🆙#WCLC26 #LCSM Plenary Session 🔥EVOKE-03/KEYNOTE D46: Primary Results from Phase 3: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥50% Metastatic NSCLC 🎙️ @g_mountzios 🎯PFS HR 0.81 (95% CI 0.66-1.00) 🎯OS HR 1.07 (95% 0.85-1.35) 🔢PL02.06 ☑️NCT05609968 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC
🆙#WCLC26 #LCSM Plenary Session 🔥EVOKE-03/KEYNOTE D46: Primary Results from Phase 3: Sacituzumab Govitecan + Pembrolizumab in PD-L1 TPS ≥50% Metastatic NSCLC 🎙️ @g_mountzios 🔢PL02.06 ☑️NCT05609968 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC
🆙#WCLC26 #LCSM Plenary Session 🔥SWOG S1827 MAVERICK: Phase III Trial of Brain MRI Surveillance +/- Prophylactic Cranial Irradiation for Small-Cell Lung Cancer 🎯Primary: CFFS (Cognitive Failure Free Survival) 🎯MRI alone: HR 0.60 (90% CI 0.46-0.78) 🎙️Dr. Chad G. Rusthoven 🔢PL02.01 ☑️NCT04155034 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC
🆙#WCLC26 #LCSM Plenary Session 🔥SWOG S1827 MAVERICK: Phase III Trial of Brain MRI Surveillance +/- Prophylactic Cranial Irradiation for Small-Cell Lung Cancer 🎙️Dr. Chad G. Rusthoven 🔢PL02.01 ☑️NCT04155034 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC
🆙#WCLC26 #LCSM OA04.03 🔥Final Analysis of the Phase 3 IMpower030 Study: Perioperative Atezolizumab + Chemotherapy in Resectable Stage II-IIIB NSCLC 🎙️@bensolomon1 🎯EFS HR 0.77 (95%CI 0.58-1.02) 🎯OS HR 0.77 (95%CI 0.57-1.07) 🎯pCR Atezo 30.6% vs. Placebo 8.6% 🔢OA04.03 ☑️NCT03456063 🔗 cattendee.abstractsonline.com/meeting/21487/… @OncoAlert @Larvol @IASLC
THE STANDARD WEALTH @Standard_Wealth
153K Followers 7 Following สำนักข่าวเศรษฐกิจ ธุรกิจ การเงิน และการลงทุน โดยทีมข่าว THE STANDARD
THE STANDARD PODCAST @TheStandardPod
239K Followers 7 Following Edutainment show for life long learning.
THE STANDARD @thestandardth
1.0M Followers 7 Following สำนักข่าวที่มุ่งสร้างความเปลี่ยนแปลงเชิงบวกแก่สังคม News media driving positive social change. ซื้อบัตร THE STANDARD ECONOMIC FORUM 2026 https://t.co/Qe31wfmq3I
Hidehito HORINOUCHI @HHorinouchi
4K Followers 86 Following Medical Oncologist, @NCCJ_official, @JCOG_official, Education committee @JSMO_official @JLCS_OFFICIAL @IASLC @ASCO FCOI https://t.co/c9VKywUIsh
Investing.com @Investingcom
1.5M Followers 322 Following https://t.co/gPm7AlQtSR helps 50 million investors find trades others can't. Get AI-picked stocks, chart analysis, Fair Value, and breaking news in 33 languages.Trends for United States
You might like
